Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study. Academic Article uri icon

Overview

abstract

  • In a 12-week placebo-controlled study of fluoxetine in the treatment of body dysmorphic disorder, the authors investigated change in psychosocial functioning and mental health-related quality of life in 60 subjects. The subjects were assessed with the LIFE-RIFT (a measure of impaired functioning), Social and Occupational Functioning Scale (SOFAS), and Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) before and after receiving fluoxetine or placebo. At baseline, the patients had impaired psychosocial functioning and markedly poor mental health-related quality of life. Compared to placebo, fluoxetine was associated with significantly greater improvement in LIFE-RIFT and SOFAS scores and with improvement on the mental health subscale of the SF-36 that approached significance. Decrease in the severity of body dysmorphic disorder, as measured by the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder, was significantly correlated with improvement in functioning and quality of life.

publication date

  • January 1, 2004

Research

keywords

  • Fluoxetine
  • Quality of Life
  • Selective Serotonin Reuptake Inhibitors
  • Somatoform Disorders

Identity

PubMed Central ID

  • PMC1613753

Scopus Document Identifier

  • 4444276511

Digital Object Identifier (DOI)

  • 10.1176/appi.psy.45.5.438

PubMed ID

  • 15345790

Additional Document Info

volume

  • 45

issue

  • 5